Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free NCYT Stock Alerts

Novacyt (NCYT) Competitors

Novacyt logo
GBX 37.10 +0.42 (+1.15%)
As of 11:27 AM Eastern
Compare

NCYT vs. CREO, IUG, IHC, RUA, and AVO

Should you buy Novacyt stock or one of its competitors? MarketBeat compares Novacyt with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novacyt include Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Inspiration Healthcare Group (IHC), RUA Life Sciences (RUA), and Advanced Oncotherapy (AVO).

How does Novacyt compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 6.9% of Creo Medical Group shares are owned by company insiders. Comparatively, 0.4% of Novacyt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Creo Medical Group has a net margin of 88.33% compared to Novacyt's net margin of -103.08%. Creo Medical Group's return on equity of 9.56% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Novacyt -103.08%-96.44%-27.98%

In the previous week, Novacyt had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for Creo Medical Group. Novacyt's average media sentiment score of 1.42 beat Creo Medical Group's score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.

Company Overall Sentiment
Creo Medical Group Neutral
Novacyt Positive

Creo Medical Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.77-£25.04M£1.0013.30
Novacyt£20.03M1.34-£36.80M-£32.00N/A

Creo Medical Group has a beta of 1.6212822, indicating that its share price is 62% more volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, indicating that its share price is 11% more volatile than the broader market.

Summary

Creo Medical Group beats Novacyt on 10 of the 13 factors compared between the two stocks.

How does Novacyt compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Intelligent Ultrasound Group has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, indicating that its share price is 11% more volatile than the broader market.

Intelligent Ultrasound Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
Novacyt£20.03M1.34-£36.80M-£32.00N/A

75.5% of Intelligent Ultrasound Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 12.8% of Intelligent Ultrasound Group shares are held by insiders. Comparatively, 0.4% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Novacyt had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for Intelligent Ultrasound Group. Novacyt's average media sentiment score of 1.42 beat Intelligent Ultrasound Group's score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
Novacyt Positive

Intelligent Ultrasound Group has a net margin of -23.11% compared to Novacyt's net margin of -103.08%. Intelligent Ultrasound Group's return on equity of -23.58% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
Novacyt -103.08%-96.44%-27.98%

Summary

Intelligent Ultrasound Group beats Novacyt on 7 of the 12 factors compared between the two stocks.

How does Novacyt compare to Inspiration Healthcare Group?

Inspiration Healthcare Group (LON:IHC) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

In the previous week, Novacyt had 1 more articles in the media than Inspiration Healthcare Group. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for Inspiration Healthcare Group. Novacyt's average media sentiment score of 1.42 beat Inspiration Healthcare Group's score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.

Company Overall Sentiment
Inspiration Healthcare Group Neutral
Novacyt Positive

Inspiration Healthcare Group has a beta of 0.872, indicating that its share price is 13% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, indicating that its share price is 11% more volatile than the broader market.

Inspiration Healthcare Group has a net margin of -2.19% compared to Novacyt's net margin of -103.08%. Inspiration Healthcare Group's return on equity of -6.49% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Inspiration Healthcare Group-2.19% -6.49% -3.47%
Novacyt -103.08%-96.44%-27.98%

7.4% of Inspiration Healthcare Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 6.1% of Inspiration Healthcare Group shares are held by insiders. Comparatively, 0.4% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inspiration Healthcare Group has higher revenue and earnings than Novacyt. Inspiration Healthcare Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspiration Healthcare Group£47.55M0.34-£12.20M-£1.16N/A
Novacyt£20.03M1.34-£36.80M-£32.00N/A

Summary

Inspiration Healthcare Group beats Novacyt on 7 of the 13 factors compared between the two stocks.

How does Novacyt compare to RUA Life Sciences?

RUA Life Sciences (LON:RUA) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

0.1% of RUA Life Sciences shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 7.3% of RUA Life Sciences shares are held by company insiders. Comparatively, 0.4% of Novacyt shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

RUA Life Sciences has a net margin of -3.26% compared to Novacyt's net margin of -103.08%. RUA Life Sciences' return on equity of -2.03% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Novacyt -103.08%-96.44%-27.98%

RUA Life Sciences has higher earnings, but lower revenue than Novacyt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M3.52-£2.66MN/AN/A
Novacyt£20.03M1.34-£36.80M-£32.00N/A

RUA Life Sciences has a beta of 0.948, indicating that its share price is 5% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, indicating that its share price is 11% more volatile than the broader market.

In the previous week, Novacyt had 1 more articles in the media than RUA Life Sciences. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for RUA Life Sciences. Novacyt's average media sentiment score of 1.42 beat RUA Life Sciences' score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.

Company Overall Sentiment
RUA Life Sciences Neutral
Novacyt Positive

Summary

RUA Life Sciences and Novacyt tied by winning 6 of the 12 factors compared between the two stocks.

How does Novacyt compare to Advanced Oncotherapy?

Novacyt (LON:NCYT) and Advanced Oncotherapy (LON:AVO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Novacyt had 1 more articles in the media than Advanced Oncotherapy. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for Advanced Oncotherapy. Novacyt's average media sentiment score of 1.42 beat Advanced Oncotherapy's score of 0.00 indicating that Novacyt is being referred to more favorably in the media.

Company Overall Sentiment
Novacyt Positive
Advanced Oncotherapy Neutral

Advanced Oncotherapy has lower revenue, but higher earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.34-£36.80M-£32.00N/A
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A

Advanced Oncotherapy has a net margin of 0.00% compared to Novacyt's net margin of -103.08%. Advanced Oncotherapy's return on equity of -67.34% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-103.08% -96.44% -27.98%
Advanced Oncotherapy N/A -67.34%-11.73%

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are owned by institutional investors. 0.4% of Novacyt shares are owned by company insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Novacyt has a beta of 1.105, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Advanced Oncotherapy has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

Summary

Advanced Oncotherapy beats Novacyt on 7 of the 12 factors compared between the two stocks.

Get Novacyt News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCYT vs. The Competition

Export
MetricNovacytHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£26.88M£5.71B£6.81B£2.83B
Dividend YieldN/A1.79%2.59%6.15%
P/E Ratio-1.1623.60281.03368.41
Price / Sales1.3458.62574.8783,654.70
Price / Cash0.5832.5328.6427.89
Price / Book0.376.5011.037.06
Net Income-£36.80M£151.15M£3.48B£5.89B
7 Day Performance-0.80%3.18%0.54%0.21%
1 Month Performance7.54%-1.28%-4.19%0.22%
1 Year Performance-6.69%5.16%63.11%64.12%

Novacyt Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCYT
Novacyt
N/AGBX 37.10
+1.1%		N/A-7.9%£26.88M£20.03MN/A120
CREO
Creo Medical Group
N/AGBX 13.73
-0.2%		GBX 40
+191.4%		+4.5%£66.68M£6M13.73279
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
IHC
Inspiration Healthcare Group
N/AGBX 18.35
-0.8%		N/A-10.0%£16.45M£47.55MN/A224
RUA
RUA Life Sciences
N/AGBX 25.95
+1.7%		N/A+110.6%£16.10M£4.11MN/A48

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NCYT) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel